KAT3 Antibody

How do I determine which KAT3 antibody is appropriate for my specific research application?

When selecting a KAT3 antibody, researchers must first identify which KAT3 protein they are targeting, as this name refers to distinct proteins in different organisms. For human KYAT3 (kynurenine aminotransferase), look for antibodies validated against the human enzyme that catalyzes transamination of L-kynurenine . For plant studies, select antibodies raised against the Arabidopsis thaliana potassium channel protein . For neuronal studies, choose antibodies targeting the KAT3 family acetyltransferases (CBP/p300) .

The application dictates antibody format requirements:

• For Western blotting: Choose polyclonal antibodies that recognize denatured epitopes

• For immunohistochemistry: Select antibodies validated for fixed tissue samples

• For chromatin immunoprecipitation: Use ChIP-grade antibodies with confirmed specificity

Always verify species reactivity matches your experimental model. For instance, human KYAT3 antibodies like ab246957 react with human, mouse, and rat samples , while plant KAT3 antibodies are specific to Arabidopsis thaliana or related species .

What control experiments should I perform to validate a KAT3 antibody?

Thorough antibody validation is essential for reliable research outcomes. Implement these controls:

• Positive controls: Include known KAT3-expressing tissues/cells:

  • For KYAT3: Liver tissue known to express high levels of the enzyme

  • For plant KAT3: Arabidopsis root tissue extracts

  • For CBP/p300: Neuronal cultures or brain tissue extracts

• Negative controls:

  • Perform experiments in KAT3 knockout or knockdown models

  • Include isotype controls with the same concentration of non-specific antibody

  • Use pre-absorption controls by pre-incubating antibody with immunizing peptide

• Specificity validation:

  • Western blot should show a single band at the expected molecular weight (e.g., 75 kDa for plant KAT3)

  • Use recombinant KAT3 protein as a positive control

  • Compare results with different antibodies targeting distinct epitopes

• Cross-reactivity assessment:

  • Test antibody against related proteins (e.g., other kynurenine aminotransferases for KYAT3)

  • Examine potential cross-reactivity with other Shaker family members for plant KAT3

What is the optimal protocol for detecting human KYAT3 in tissue sections using immunohistochemistry?

For successful immunohistochemical detection of KYAT3 in tissue sections:

• Tissue preparation:

  • Fix tissues in 10% neutral buffered formalin for 24 hours

  • Process and embed in paraffin following standard protocols

  • Section at 4-5 μm thickness

• Antigen retrieval (critical for formalin-fixed tissues):

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0)

  • Maintain at 95-98°C for 20 minutes, then cool to room temperature

• Blocking and antibody incubation:

  • Block endogenous peroxidase activity with 3% H₂O₂ for 10 minutes

  • Block non-specific binding with 5% normal serum for 1 hour

  • Incubate with anti-KYAT3 antibody (e.g., ab246957) at 1:100-1:200 dilution overnight at 4°C

  • Wash thoroughly with PBS-T (3 × 5 minutes)

• Detection system:

  • Use appropriate HRP-conjugated secondary antibodies

  • Develop with DAB substrate

  • Counterstain with hematoxylin for nuclear visualization

• Controls to include:

  • Positive control: Liver tissue sections (high KYAT3 expression)

  • Negative control: Antibody diluent without primary antibody

  • Technical control: Isotype-matched irrelevant antibody

When interpreting results, note that KYAT3 shows both cytoplasmic and nuclear localization in certain cell types, particularly where it interacts with p53 .

How can I optimize Western blotting protocols for detecting KYAT3 in cell lysates with minimal background?

For clean Western blot detection of KYAT3:

• Sample preparation:

  • Lyse cells in RIPA buffer supplemented with protease inhibitors

  • Include phosphatase inhibitors if examining phosphorylation states

  • Sonicate briefly to shear DNA and reduce viscosity

  • Quantify protein concentration using BCA or Bradford assay

• Gel electrophoresis and transfer:

  • Load 20-30 μg protein per lane on 10% SDS-PAGE gels

  • Include molecular weight markers and positive controls

  • Transfer to PVDF membrane (preferred over nitrocellulose for KYAT3)

  • Confirm transfer efficiency with Ponceau S staining

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk in TBS-T for 1 hour at room temperature

  • For phospho-specific detection, use 5% BSA instead of milk

  • Incubate with anti-KYAT3 antibody at 1:1000 dilution overnight at 4°C

  • Wash extensively with TBS-T (4 × 5 minutes)

• Background reduction strategies:

  • Increase washing time and volume

  • Use freshly prepared buffers

  • Optimize antibody concentration through titration

  • Consider adding 0.05% SDS to antibody diluent

  • Use highly specific secondary antibodies at 1:5000-1:10,000 dilution

• Detection:

  • Use enhanced chemiluminescence (ECL) for standard detection

  • For low abundance samples, consider using more sensitive ECL substrates

What challenges exist when detecting plant KAT3 (potassium channel) in native tissues?

Detecting plant KAT3 potassium channels presents several unique challenges:

• Extremely low expression levels:

  • Ion channels typically express at only a few hundred proteins per cell in native plant tissue

  • Standard detection methods often fail to produce adequate signal

  • Requires specialized high-sensitivity detection systems

• Optimized extraction methods:

  • Implement two-phase partitioning for membrane protein enrichment

  • Use detergent-based extraction buffers optimized for membrane proteins

  • Include protease inhibitor cocktails specific for plant tissues

• Detection strategies:

  • 125I-labeled secondary antibodies may be necessary for sufficient sensitivity

  • Consider using tyramide signal amplification for immunohistochemistry

  • Extended exposure times are often required for detection

• Antibody selection:

  • Choose antibodies raised against peptides from less conserved regions to avoid cross-reactivity with other Shaker family members

  • Verify specificity against heterologously expressed KAT3 in systems like Sf9 cells or yeast

  • Use antibodies validated specifically for Arabidopsis thaliana KAT3 (KC1)

• Controls and validation:

  • Heterologous expression systems serve as positive controls

  • Knockout/knockdown plant lines provide essential negative controls

  • Western blotting should show bands at approximately 75.5 kDa

How can I improve detection sensitivity for plant KAT3 in Western blot applications?

To enhance detection sensitivity for the low-abundance plant KAT3 channel:

• Sample enrichment:

  • Start with larger amounts of plant material (50-100g)

  • Employ two-phase partitioning to concentrate membrane proteins

  • Use ultracentrifugation to isolate membrane fractions

  • Consider immunoprecipitation before Western blotting

• Protein extraction optimization:

  • Use specialized extraction buffers containing 1% Triton X-100 or n-dodecyl-β-D-maltoside

  • Include plant-specific protease inhibitor cocktails

  • Perform extraction at 4°C to minimize degradation

• Sensitive detection methods:

  • Use 125I-labeled secondary antibodies for maximum sensitivity as described in published protocols

  • Consider ECL+ for expression in heterologous systems (1:1000 primary antibody dilution)

  • Implement femto-sensitivity chemiluminescent substrates

  • Consider fluorescent secondary antibodies with laser scanning detection

• Signal amplification techniques:

  • Biotin-streptavidin amplification systems

  • Tyramide signal amplification (TSA)

  • Polymer-based detection systems with multiple enzyme molecules

• Antibody considerations:

  • Longer primary antibody incubation (overnight at 4°C)

  • Higher concentration of primary antibody (1:50 for native tissues)

  • Validate with recombinant expression in insect cells or yeast before attempting native tissue detection

How do I design experiments to investigate KAT3-dependent acetylation patterns in neurons?

The KAT3 family (CBP/p300) plays crucial roles in maintaining neuronal identity through acetylation of cell type-specific genes . When designing experiments to study these patterns:

• Experimental models:

  • Consider inducible ablation models like those described in published literature

  • Compare single (CBP or p300) versus double knockout models

  • Use Cre-loxP systems for cell-type specific and temporally controlled deletion

• Chromatin immunoprecipitation approaches:

  • Employ CUT&RUN-seq for investigation of chromatin occupancy with low input material

  • Use H3K27ac antibodies to identify active enhancers dependent on KAT3 activity

  • Implement ChIP-seq to map genome-wide KAT3 binding sites

• Acetylation pattern analysis:

  • Investigate histone marks known to be dependent on KAT3 activity:

    • H3K27ac shows particular sensitivity to CBP/p300 loss

    • Compare with other acetylation marks like H3K9ac

  • Examine non-histone protein acetylation using acetylome analysis

  • Validate findings using site-specific acetylation antibodies

• Data integration strategies:

  • Use binding and expression target analysis (BETA) to integrate ChIP-seq and RNA-seq data

  • Classify KAT3 binding patterns as neuronal-specific, non-neuronal-specific, or "pancellular"

  • Correlate acetylation changes with gene expression alterations

• Controls to include:

  • Single allele models (maintaining one functional KAT3 allele serves as an important control)

  • Temporal controls to distinguish development versus maintenance roles

  • Cell-type specific controls to identify neuron-specific versus ubiquitous functions

What are the critical parameters for successful immunoprecipitation of KAT3 family members from neuronal samples?

Immunoprecipitation of KAT3 family members (CBP/p300) requires careful optimization:

• Sample preparation:

  • For brain tissue: Rapidly dissect and flash-freeze in liquid nitrogen

  • Homogenize in ice-cold lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100)

  • Include deacetylase inhibitors (1 μM TSA, 5 mM sodium butyrate)

  • Add protease inhibitor cocktail and phosphatase inhibitors

  • Clear lysates by centrifugation at 14,000g for 10 minutes at 4°C

• Antibody selection and coupling:

  • Choose antibodies validated for immunoprecipitation applications

  • Pre-couple antibodies to protein A/G magnetic beads (4 μg antibody per 50 μl beads)

  • Prepare IgG control beads in parallel

  • Crosslink antibodies to beads using BS3 or DMP to prevent antibody leaching

• Immunoprecipitation conditions:

  • Pre-clear lysates with protein A/G beads for 1 hour at 4°C

  • Incubate pre-cleared lysates with antibody-coupled beads overnight at 4°C with gentle rotation

  • Use at least 500 μg total protein per IP reaction

  • Wash beads 5 times with wash buffer containing decreasing salt concentrations

  • Elute with either 0.1 M glycine (pH 2.5) or by boiling in 1X SDS sample buffer

• Verification of IP success:

  • Analyze by Western blot using a different antibody recognizing a distinct epitope

  • Include input, unbound, and eluate fractions

  • Verify CBP/p300 enrichment by probing for known interacting partners

• Downstream applications:

  • For interaction studies: Co-IP followed by Western blotting or mass spectrometry

  • For binding site identification: ChIP-seq using optimized protocols for transcription factors

  • For acetylation activity: In vitro acetylation assays with immunoprecipitated KAT3

How can I address non-specific binding issues when using KAT3 antibodies in immunostaining applications?

Non-specific binding is a common challenge when using KAT3 antibodies across various applications. To troubleshoot:

• Optimize blocking conditions:

  • Test different blocking agents (BSA, normal serum, commercial blockers)

  • Increase blocking time to 2 hours at room temperature

  • Add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions

  • For neuronal tissues, consider adding 5% donkey serum to standard blocking solutions

• Antibody optimization:

  • Titrate primary antibody concentration (typically 1:100-1:1000)

  • Extend primary antibody incubation to overnight at 4°C

  • Use antibodies validated specifically for your application (IHC-P, ICC/IF)

  • Consider antibody purification methods (affinity-purified vs. serum)

• Sample preparation refinements:

  • Optimize fixation conditions (duration, fixative concentration)

  • Ensure complete permeabilization for intracellular antigens

  • Test different antigen retrieval methods (heat-induced vs. enzymatic)

  • Include detergent in all wash steps

• Amplify specific signal while reducing background:

  • Use biotinylated secondary antibodies with streptavidin-conjugated fluorophores

  • Implement tyramide signal amplification for low-abundance targets

  • Add 0.01% Tween-20 to antibody diluent

  • Include 10-50 mM glycine in wash buffer to reduce aldehyde-induced background

• Additional controls and validation:

  • Perform peptide competition assays to confirm specificity

  • Include absorption controls using the immunizing peptide

  • Compare staining patterns with different antibodies targeting the same protein

  • Validate results with genetic knockdown/knockout samples

What strategies can resolve contradictory results when using different KAT3 antibodies in the same experimental system?

When facing contradictory results with different KAT3 antibodies:

• Epitope mapping and antibody characterization:

  • Identify the specific epitopes recognized by each antibody

  • Determine if epitopes might be masked by protein interactions

  • Check if post-translational modifications affect epitope recognition

  • Verify recognition of native versus denatured conformations

• Comprehensive validation studies:

  • Test antibodies in known positive and negative control samples

  • Use genetic approaches (siRNA, CRISPR) to validate specificity

  • Compare results from different applications (WB, IP, IHC)

  • Evaluate batch-to-batch variability from the same supplier

• Technical considerations:

  • Standardize protocols across all antibodies being tested

  • Use the same detection system and imaging parameters

  • Ensure identical sample preparation methods

  • Process samples in parallel to minimize technical variation

• Resolution strategies:

  • Implement sandwich assays using antibody pairs recognizing different epitopes

  • Use recombinant protein standards with known concentrations

  • Perform mass spectrometry validation of immunoprecipitated targets

  • Consider antibody engineering approaches for improved specificity

• Data integration and interpretation:

  • Weight evidence based on validation quality for each antibody

  • Consider biological context when interpreting conflicting results

  • Use orthogonal approaches to confirm key findings

  • Document and report discrepancies transparently in publications